Last reviewed · How we verify

NCT06160154

Minimally Invasive Robot-assisted and Laparoscopic Distal Pancreatectomy in a Pan-European Registry

Completed Last updated 7 December 2023
What this trial tests

trial testing no intervention in Pancreas Disease in 1,672 participants. Completed in 1 January 2022.

Timeline
1 January 2019
Primary endpoint
31 December 2021
1 January 2022

Quick facts

Lead sponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,672
Start date1 January 2019
Primary completion31 December 2021
Estimated completion1 January 2022
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

18 and older, any sex, with Pancreas Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A planned analysis of outcomes among consecutive patients after MIDP from centers participating in the E-MIPS registry (2019-2021). Main outcomes of interest were intraoperative events, major morbidity (Clavien-Dindo grade ≥3) and 30-day/in-hospital mortality.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Pancreas Disease

Currently open trials in the same condition.

Other Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06160154.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing